Switzerland· 65741001
Esmolol OrPha LYO 2500 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
A esmolol product containing esmololi hydrochloridum, registered in Switzerland by OrPha Swiss GmbH and dispensed under Swissmedic category B. The same ATC class is registered in 16 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Esmolol is registered in 16 of 19 countries.
Countries holding a registration under ATC C07AB09 (esmolol), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Esmolol · ATC C07AB09
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- esmololi hydrochloridum
- Manufacturer
- OrPha Swiss GmbH
- Country
- Switzerland (CH)
- ATC code
- C07AB09
- ATC class
- Esmolol
- Swissmedic category
- B
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
196 interactions on record for esmolol.
Graded by severity as the source publishes them — 11 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Esmolol · interactions on record
196 records
- 11 severe
- 139 moderate
- 8 minor
Most severe, free to view
- DolasetronA04AA04severe
- TheophyllinC01EB28severe
- CeritinibL01ED02severe
- CeritinibL01XE28severe
38 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Esmolol in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumEsmocard 2500 mgOrpha-Devel Handels und Vertriebs
- CzechiaESMOCARD LYOOrpha-Devel Handels und Vertriebs GmbH, Purkersdorf
- FinlandEsmocardOrpha-Devel Handels und Vertriebs GmbH
- NetherlandsEsmolol HCl LYO Orpha 2500 mg poeder voor concentraat voor oplossing voor infusieOrpha Devel Handels-und Vertriebs GmbH
- United StatesBreviblocBaxter Healthcare Company
- United KingdomBrevibloc Concentrate 2.5g/10ml solution for infusion ampoulesBaxter Healthcare Ltd
- GermanyBreviblocBaxter Deutschland Gmbh
- FranceBREVIBLOC 10 mg/ml, solution pour perfusionBAXTER
Authorised across Europe · EMA
The same active substance is authorised in 22 EEA countries. Names it is sold under:
- Austria · Brevibloc, Esmolol Amomed
- Belgium · Brevibloc
- Cyprus · Brevibloc, Esmobeta
- Czechia · Esmocard, Esmocard Lyo
- Germany · Brevibloc, Esmocard
- Denmark · Brevibloc
- Spain · Brevibloc, Esmolol Aurovitas
- Finland · Brevibloc
- France · Brevibloc, Esmocard
- United Kingdom (Northern Ireland) · Brevibloc Premixed, Esmolol Hikma Farmacêutica (Portugal)
- Greece · Brevibloc, Esmobeta
- Croatia · Esmocard
- Ireland · Brevibloc Premixed
- Italy · Brevibloc, Esmocard
- Luxembourg · Brevibloc
- Malta · Brevibloc Premixed
- Netherlands · Brevibloc, Esmolol Hcl Hikma
- Norway · Brevibloc
- Portugal · Brevibloc, Esmolol Eugia
- Sweden · Brevibloc
- Slovenia · Esmocard, Esmocard Lyo
- Slovakia · Esmocard, Esmocard Lyo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8b48277f-128d-447e-aaf8-f1069ab89d68 GET /v1/drugs/8b48277f-128d-447e-aaf8-f1069ab89d68?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Synthetika"
}See everything about esmolol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.